Hubei Vanz Pharm Co., Ltd.

Country/Region: China

Main Products: FlibanserinHydronchloride, MK-677, 7, 8-Dihydroxyflavone, Nicotinamide Riboside Chloride, N NDimethylphenethylamine Citrate, FlibanserinHydronchloride

Company Introduction
In the most revolutionizing industry Hubei Vanz Pharm Co., Ltd. Private Limited has reached a milestone owing to the top notch production facility with technologically advanced equipment to manufacture first in class Itraconazole Powder, committing reliability, durability and optimum functioning. Since our inception, back in 2008 we have designed products to provide electrical solution having no match because we only source raw material that caters to durability, safety and meets international standards. Our export operations invaded international market as well, now holding Australia,South Korea,New Zealand,Philippines,Saudi Arabia export market share with gross export ratio value of US$1 Million - US$2.5 Million. Products we count on include FlibanserinHydronchloride,MK-677,7,8-Dihydroxyflavone,Nicotinamide Riboside Chloride,N NDimethylphenethylamine Citrate, helping us generate overall annual revenue across Approx 0.8 Million US Dollar. Electronic products in the market never go out of demand and to successfully meet that, our production potential is always on point, thanks to our manufacturing facility with Third Party, situated in Wuhan, , China.As a leading Manufacturer and Retailer, we hold export history of 12 Years , covering a milestone from where we began first with initial business capital of US$1 Million - US$2.5 Million.
Company Overview

Business Type: Manufacturer

Business Nature: Manufacturer

Year Established: 2008, 2008

Legal Status: Third Party

Ownership: Private Limited

Employees: Above 1000 People

Factory Size: 30, 000-50, 000 square meters

R&D Team Size: 5 - 10 People

Certifications: FSC

Contact Information

Contact Person: Ms. lansky Du

Designation: Manager

Department: Export Manager

Telephone: 868618071739296

Business Information

Main Markets: Australia (28%) Philippines (24%) Saudi Arabia (21%) New Zealand (18%) South Korea (14%)

Export Focus: Australia, South Korea, New Zealand, Philippines, Saudi Arabia

Contract Services: Design Service Offered

Trade & Financial Information

Annual Revenue: Approx 0.8 Million US Dollar

Registered Capital: US$1 Million - US$2.5 Million

Export Percentage: 41% - 50%

Payment Terms: Bank wire (T/T)

Product Showcase
FlibanserinHydronchloride
MK-677
7
8-Dihydroxyflavone
Nicotinamide Riboside Chloride
N NDimethylphenethylamine Citrate
FlibanserinHydronchloride
MK-677
7
8-Dihydroxyflavone
Nicotinamide Riboside Chloride
N NDimethylphenethylamine Citrate

CL-Link > Health & Medicines in China Medicines in China Itraconazole Powder in China